PROTOCOL SUMMARY FOR PATIENTS

View Professional Summary

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies


Basic Trial Information

Protocol Phase:Phase II
Study Category:Treatment
Current Protocol StatusActive
Age6 and over
Protocol SponsorPharmaceutical/Industry
Primary IDSGN35-013
Other IDNCT01461538
Special Category

TRIAL DESCRIPTION

Purpose:
Eligibility:
Treatment Intervention:
Patient Disclaimer: